You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Proscia'a digital pathology platform allows pathologists to view, manage, and analyze whole-slide images and is interoperable with laboratory information systems.
The algorithm provides automated assessments of objective and reproducible scanned slide images that can help with diagnosis and targeted treatment options.
Kidney disease diagnostic company RenalytixAI is planning a public offering of its American Depositary Shares and a concurrent private placement.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.
The research institute will provide blood samples to Prevencio, which will then use its artificial intelligence platform to develop a diagnostic test.
The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals.
The Boston-based startup will use the funding to flesh out its diagnostic platform to detect antibiotic-resistant bacterial infections within a clinically relevant timeframe.
The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.
The deal is aimed at providing technologies, products, and services that will improve the standardization of pathology labs and accelerate accurate diagnoses.
Proscia said that the collaboration will focus initially on prostate cancer and then expand to several cancer subspecialties.